Ropes & Gray Represents Xeris Biopharma in Research Collaboration with Regeneron Pharmaceuticals
Ropes & Gray represented Xeris Biopharma Holdings in a platform research evaluation, collaboration and option agreement with Regeneron Pharmaceuticals, Inc. Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron. The collaboration and license agreement was announced on March 30th.
Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron has an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization. Specific financial terms of the agreement were not disclosed.
The Ropes & Gray team was led by IP transactions partner Abigail Gregor and IP transactions associate Ian Nilsen.